Tricol Biomedical Receives NIH Phase IIB Grant to Continue Development of its Hemostatic Device for the Prostate

NEXT STORY
Cerner’s New President and CEO to Kick Off Annual Cerner Health Conference
PREV STORY
SECU Foundation Helps Advance UNC Health Foundation Pilot for NC Public School Students
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Loxo Oncology Reports Third Quarter 2018 Financial Results

Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018 LOXO-292 Registrational Data ...

author_avatar
NASDAQ Market News

Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab’s Biologics License Application in the US

NOVATO, Calif. and TOKYO, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), ...

author_avatar
NASDAQ Market News

Zomedica Provides Product Development Update

ANN ARBOR, Mich., June 19, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) ...

author_avatar
NASDAQ Market News